文献速递类风湿关节炎

炎症性风湿病患者术前是否应停用传统合成及靶向DMARDs?

'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'.
PubMed 文献 · RMD Open · 2020-01-01

全髋和全膝关节置换术仍是治疗类风湿关节炎症状性膝髋损害的重要干预措施,尽管强效传统合成DMARDs和靶向DMARDs广泛使用,手术利用率变化不大。多数患者在关节置换时正接受免疫抑制药物和糖皮质激素治疗。本文综述围手术期靶向及传统合成DMARDs和糖皮质激素管理的已知信息。

要点

  • 多数类风湿关节炎患者关节置换时正使用csDMARDs、靶向DMARDs或糖皮质激素。
  • 围手术期DMARDs使用的随机对照试验数据极少。
  • 本文综述围手术期靶向及csDMARDs和糖皮质激素的管理证据。

核心结论

  • 关于炎症性风湿病患者关节置换围手术期DMARDs和糖皮质激素管理的随机对照试验数据极少,但患者和医生每日面临此类决策。

研究设计与样本

  • 本文为综述,总结围手术期靶向及传统合成DMARDs和糖皮质激素管理的已知信息。

主要发现

  • 尽管强效传统合成DMARDs和靶向DMARDs(包括Janus激酶抑制剂和生物制剂)日益广泛使用,类风湿关节炎患者全髋和全膝关节置换术利用率变化不大。
  • 多数患者在接受关节置换时正使用免疫抑制药物和糖皮质激素。

局限性

  • 围手术期DMARDs使用的随机对照试验数据极少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Total hip and total knee arthroplasty) remain important interventions to treat symptomatic knee and hip damage in patients with rheumatoid arthritis, with little change in utilisation rates despite the increasingly widespread use of potent conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and targeted DMARDs including Janus kinase inhibitors and biologics. The majority of patients are receiving these immunosuppressing medications and glucocorticoids at the time they present for arthroplasty. There is minimal randomised controlled trial data addressing the use of DMARDs in the perioperative period, yet patients and their physicians face these decisions daily. This paper reviews what is known regarding perioperative management of targeted and csDMARDs and glucocorticoids.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Goodman S M, George M D. 'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'. RMD Open. 2020. PMID: 32719151. doi:10.1136/rmdopen-2020-001214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。